Evaluation of Drug Therapy in Non-Communicable Diseases; a Review Study
- سال انتشار: 1401
- محل انتشار: مجله علوم دارویی و شیمی، دوره: 5، شماره: 2
- کد COI اختصاصی: JR_JMCH-5-2_008
- زبان مقاله: انگلیسی
- تعداد مشاهده: 390
نویسندگان
Assistant Professor of Emergency Medicine, Department of Emergency Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences, Iran
Department of Cellular and Molecular Biology, Faculty of Basic Sciences, Rafsanjan University, Iran
BSc in Anesthesiology at Shahrekord Medical University, Iran
Researcher at the Anesthesia and Pain & Molecular and cell Biology Research center, Faculty of Medicine Department of Anatomy, Iran university of Medical Sciences, Tehran, Iran
Department of Emergency Medicine, Khatam-Al-Anbia Hospital, Zahedan University of Medical Sciences, Zahedan, Iran
چکیده
This study is a conceptual review. Various protocols have been proposed for non-communicable diseases worldwide. The importance of this large group of diseases has prompted the World Health Organization (WHO) to plan effectively to set targets to reduce mortality from these diseases by one-third by ۲۰۳۰ in the Sustainable Development Plan. In asthma, corticosteroids are still recognized as the most potent anti-asthma drugs, and there is still no drug with the same effect, and biological agents (drugs such as amalizumab) significantly improve the management of severe asthma. Regarding diabetes, the recommendations of the WHO were reviewed, and the first recommendation is that if metformin, which is recommended as the first oral antidiabetic drug in all guidelines, cannot control hyperglycemia, sulfonylurea should be prescribed to patients with type ۲ diabetes. Non-communicable diseases in Iran cause ۴۵% of the disease burden in men and ۳۳% of the disease burden in women, of the total causes of the disease burden in both sexes (۶-۱۰). Obesity and overweight, arterial hypertension, inadequate physical activity and addiction are ۸۶% of the risk factors for diseases and ۱۱% of all diseases. These risk factors have caused ۶.۱ million years of adapted life expectancy in Iran.کلیدواژه ها
Drug Therapy, non-communicable diseases, treatmentاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.